logo

Moleculin Biotech Inc (MBRX)



Trade MBRX now with
  Date
  Headline
12/4/2019 7:32:15 AM Moleculin Announces Addl Positive Interim Results From Phase 1/2 Clinical Studies Of Annamycin In Acute Myeloid Leukemia
11/19/2019 7:31:25 AM Moleculin Announces Positive Trial Data With Safe Delivery Of P-STAT3 Inhibitor And Efficacy In Majority Of Patients
11/12/2019 8:09:45 AM Moleculin Biotech Reports FDA Approval Of IND For Its STAT3 Inhibitor In Emory University Clinical Trial
11/12/2019 7:13:08 AM Moleculin Biotech Q4 Loss Per Share $0.09 Vs Loss $0.08 Last Year
10/22/2019 7:43:40 AM Moleculin Biotech Announces Expansion Of Annamycin Production Commitments
7/10/2019 7:31:32 AM Moleculin Files For New Patents For Annamycin After Receiving FDA Approval Of Fast Track Designation
5/14/2019 7:33:22 AM Moleculin Biotech Q1 Loss Per Share $0.14 Vs Loss $0.08 Last Year
4/23/2019 8:42:21 AM Moleculin Biotech Announces $15.0 Mln Registered Direct Offering
4/18/2019 7:34:18 AM Moleculin Biotech: US FDA OKs Fast Track Designation For Annamycin For Treatment Of Refractory Acute Myeloid Leukemia
4/11/2019 7:33:37 AM Moleculin Announces Agreement With Emory University To Conduct Phase 1 Clinical Trial Of WP1066 In Pediatric Brain Tumor
4/3/2019 7:31:54 AM Moleculin Announces Preclinical Pancreatic Cancer Data Presented At AACR Annual Meeting
  
 
>